BeiGene
BGNE
#934
Rank
โ‚น1.776 T
Marketcap
โ‚น15,972
Share price
-2.10%
Change (1 day)
-2.31%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Net assets

Net assets on the balance sheet as of June 2024 : โ‚น284.12 Billion

According to BeiGene 's latest financial reports the company has โ‚น284.12 Billion in net assets.
A companyโ€™s net assets is the sum of its assets minus the sum of its liabilities.

BeiGene - Net assets on balance sheet (from 2014 to 2024)

Net assets by year

Year Net assets Change
2023-12-31$โ‚น294.47 B-18.81%
2022-12-31$โ‚น362.72 B-20.53%
2021-12-31$โ‚น456.45 B61.31%
2020-12-31$โ‚น282.97 B305.59%
2019-12-31$โ‚น69.76 B-43.1%
2018-12-31$โ‚น122.61 B180.67%
2017-12-31$โ‚น43.68 B82.17%
2016-12-31$โ‚น23.98 B385.57%
2015-12-31$โ‚น4.93 B202.42%
2014-12-31$โ‚น1.63 B-168.26%
2013-12-31$-โ‚น2.4 Billion

Net assets for similar companies or competitors

Company Net assets differencediff. Country
โ‚น0.50 B-99.82%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น117.77 B-58.55%๐Ÿ‡บ๐Ÿ‡ธ USA